Claims for Patent: 7,824,679

Summary for Patent: 7,824,679

Title:	Human monoclonal antibodies to CTLA-4
Abstract:	In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
Inventor(s):	Hanson; Douglas Charles (Niantic, CT), Neveu; Mark Joseph (Hartford, CT), Mueller; Eileen Elliott (Old Lyme, CT), Hanke; Jeffrey Herbert (Reading, MA), Gilman; Steven Christopher (Cambridge, MA), Davis; C. Geoffrey (Burlingame, CA), Corvalan; Jose Ramon (Foster City, CA)
Assignee:	Amgen Fremont Inc. (Fremont, CA) Pfizer Inc. (New York, NY)
Application Number:	11/981,810
Patent Claims:	1. A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to CTLA-4, wherein said antibody comprises heavy chain CDR1, CDR2, and CDR3 amino acid sequences from a heavy chain variable domain; and wherein said antibody comprises light chain CDR1, CDR2, and CDR3 amino acid sequences from a light chain variable domain; wherein said heavy chain variable domain and said light chain variable domain comprise: (a) the amino acid sequence of SEQ ID NO: 73 and the amino acid sequence of SEQ ID NO: 95, respectively; (b) the amino acid sequence of SEQ ID NO: 75 and the amino acid sequence of SEQ ID NO: 89, respectively; (c) the amino acid sequence of SEQ ID NO: 76 and the amino acid sequence of SEQ ID NO: 92, respectively; (d) the amino acid sequence of SEQ ID NO: 78 and the amino acid sequence of SEQ ID NO: 90, respectively; (e) the amino acid sequence of SEQ ID NO: 79 and the amino acid sequence of SEQ ID NO: 91, respectively; (f) the amino acid sequence of SEQ ID NO: 81 and the amino acid sequence of SEQ ID NO: 97, respectively; (g) the amino acid sequence of SEQ ID NO: 82 and the amino acid sequence of SEQ ID NO: 98, respectively; (h) the amino acid sequence of SEQ ID NO: 83 and the amino acid sequence of SEQ ID NO: 114, respectively; or (i) the amino acid sequence of SEQ ID NO: 84 and the amino acid sequence of SEQ ID NO: 116, respectively. 2. The antibody or antigen-binding portion according to claim 1 that is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody. 3. The antibody according to claim 1 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule. 4. A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 1 and a pharmaceutically acceptable carrier. 5. A method for treating a tumor in a subject, comprising the step of administering to the subject the antibody or antigen-binding portion according to claim 1. 6. A monoclonal antibody or an antigen-binding portion thereof, wherein said antibody comprises a heavy chain and a light chain comprising: (a) the amino acid sequence of SEQ ID NO: 73 and the amino acid sequence of SEQ ID NO: 95, respectively; (b) the amino acid sequence of SEQ ID NO: 75 and the amino acid sequence of SEQ ID NO: 89, respectively; (c) the amino acid sequence of SEQ ID NO: 76 and the amino acid sequence of SEQ ID NO: 92, respectively; (d) the amino acid sequence of SEQ ID NO: 78 and the amino acid sequence of SEQ ID NO: 90, respectively; (e) the amino acid sequence of SEQ ID NO: 79 and the amino acid sequence of SEQ ID NO: 91, respectively; (f) the amino acid sequence of SEQ ID NO: 81 and the amino acid sequence of SEQ ID NO: 97, respectively; (g) the amino acid sequence of SEQ ID NO: 82 and the amino acid sequence of SEQ ID NO: 98, respectively; (h) the amino acid sequence of SEQ ID NO: 83 and the amino acid sequence of SEQ ID NO: 114, respectively; or (i) the amino acid sequence of SEQ ID NO: 84 and the amino acid sequence of SEQ ID NO: 116, respectively. 7. The antibody according to claim 6, wherein the heavy chain and light chain comprise: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 66 and a light chain comprising the amino acid sequence of SEQ ID NO: 67, respectively; or (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO: 69, respectively. 8. A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to CTLA-4, wherein the heavy chain of said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 73, 75, 76, 78, 79, and 81-84. 9. The antibody according to claim 8, wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 66 or 68. 10. The antibody according to claim 8 that is a bispecific antibody. 11. The antibody according to claim 8 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule. 12. A pharmaceutical composition comprising the antibody or portion according to claim 8 and a pharmaceutically acceptable carrier. 13. A method for treating a tumor in a subject, comprising the step of administering to the subject the antibody or portion according to claim 8. 14. A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to CTLA-4, wherein the light chain of said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 89-92, 95, 97, 98, 114, and 116. 15. The antibody according to claim 14, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 67 or 69. 16. The antibody according to claim 14 that is a bispecific antibody. 17. The antibody according to claim 14 that is an immunoglobulin G (IgG), an IgM, an IgE, an IgA or an IgD molecule. 18. A pharmaceutical composition comprising the antibody or portion according to claim 14 and a pharmaceutically acceptable carrier. 19. A method for treating a tumor in a subject, comprising the step of administering to the subject the antibody or portion according to claim 14.

Details for Patent 7,824,679

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	12/12/2018		2018-12-23